clinical trial · NCT07935317
A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer
Eli Lilly and Company·phase2·not yet recruiting·n = 120
Breast NeoplasmsAbemaciclibTersolisibLetrozoleAnastrozoleExemestane
brief summary
The main purpose of this study is to compare two ways of giving the anti-cancer medicines abemaciclib and hormone therapy with tersolisib in participants with early breast cancer that has a genetic mutation (PIK3CA mutation). For each participant, the study will last up to 56 weeks and include 12 visits.
started
Dec 1, 2026
primary completion
Dec 1, 2027
completion
Jan 1, 2028
last updated
Nov 13, 2026
official title
A Phase 2, Open-label, Randomized Study Investigating the Tolerability of Concurrent Versus Staggered Administration of Abemaciclib and Endocrine Therapy With Tersolisib in Patients With HR+, HER2- Node-Positive, PIK3CA-Mutated Early Breast Cancer.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol